Loading clinical trials...
Loading clinical trials...
PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke (PISTIAS-3): a Randomized, Double-blind, Placebo-controlled Trial
Conditions
Interventions
Rucacuzumab plus standard therapy
Recaticimab plus placebo in combination with standard therapy
Locations
19
China
Chinese PLA General Hospital
Beijing, Beijing Municipality, China
The Third Affiliated Hospital of Sun Yat-sen University, Yuedong Hospital
Meizhou, Guangdong, China
Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine
Cangzhou, Hebei, China
Peking University Third Hospital Qinhuangdao Hospital
Qinhuangdao, Hebei, China
Hebei Provincial People's Hospital
Shijiazhuang, Hebei, China
Tangshan Worker's Hospital
Tangshan, Hebei, China
Start Date
September 1, 2026
Primary Completion Date
December 31, 2028
Completion Date
December 31, 2029
Last Updated
March 12, 2026
NCT07052045
NCT06424860
NCT06902740
NCT05821894
NCT07309705
NCT07314476
Lead Sponsor
Peking Union Medical College Hospital
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions